R&I: Acute Myeloid Leukemia Therapeutics Market - Size, Share, Global Trends 2020

1

Acute Myeloid Leukemia Therapeutics Market to
2020 - Novel Therapies to Offer Clinical Benefit
in Small Patient Cohorts

Publisher GBI Research
No of pages 163
Publish Date Sep 2014
2
Description


GBI Research, has released its latest pharma
report, "Acute Myeloid Leukemia Therapeutics
Market to 2020 - Novel Therapies to Offer
Clinical Benefit in Small Patient
Cohorts" Treatment and prognosis in AML is
strongly influenced by a patients age, and their
cytogenetic profile. In the majority of cases
these two prognostic influences are linked, with
a higher frequency of unfavorable cytogenetic
abnormalities observed in the elderly. Survival
in this cohort of elderly patients is very poor,
with a five year overall survival of 38 (Luger,
2010). Despite a relatively advanced
understanding of genetic abnormalities associated
with AML, the introduction of targeted therapies
is lagging in this indication in comparison to
other cancers such as breast and lung cancer,
with no approved targeted therapies. Such slow
development may be a reflection of AMLs status as
an orphan indication. Intensive treatment in
eligible patients (younger patients, and
approximately 50 of diagnosed elderly patients)
is typically the combination of the two
chemotherapeutic agents cytarabine and
daunorubicin, both of which were approved in the
1960s.
3
Description


In patients ineligible for intensive first-line
chemotherapy, options are very poor, with the
more recently approved Vidaza and Dacogen as the
treatment options, which both offer
unsatisfactory survival. Across all newly
diagnosed patients that obtain complete
remission, a stem cell transplant offers the
highest chance of long-term survival. However,
this procedure is risky, with a higher rate of
treatment related mortality in the absence of
better techniques to reduce the risk of
graft-versus-host disease. The majority of
patients experience disease relapse, which is
almost always fatal. Treatment options in these
patients typically involve the off-label use of
chemotherapeutic agents, whether in combination
or as monotherapies. There are clear gaps in the
market for therapies to meet several unmet needs
by increasing the initial length of remission
improving treatment options for newly-diagnosed
patients, ineligible for relapsed disease
treatments improving the success of and reducing
the side effects of stem cell transplantation
and improving survival, safety and quality of
life in patients with relapsed disease.
4
Description


The current developmental pipeline addresses
these gaps in the market, along with the
significant lack of targeted therapies. Five of
the eight pipeline products are under development
as non-intensive therapies for the elderly, and
six of the eight products are being investigated
in relapsed disease. Results so far have been
mixed, with several drugs offering no
overwhelming clinical benefit in Phase I and II
clinical trials. Some drugs have demonstrated
encouraging results namely CPX-351,
quizartinib, StemEx, treosulfan and midostaurin.
All of these drugs are forecast to be approved
within the forecast period, a result of clinical
trial data that suggest these drugs can offer
improved survival in comparison to the currently
marketed products. It is important to note
however, that these improvements and the
subsequent approval of these products is
restricted to small patient cohorts Request for
discount at http//www.reportsandintelligence.co
m/purchase-enquiry/159540
5
Scope

• The report analyzes treatment usage patterns,
  marketed and pipeline drugs, and market forecasts
  across indications for AML. The report covers and
  includes
• A brief introduction to AML, including the
  diseases pathogenesis, risk factors and
  diagnosis
• An in-depth analysis of the drug combinations
  used in the treatment of AML, including analyses
  of their safety, efficacy, and place in the
  disease treatment algorithm. This includes a heat
  map comparing the drug combinations in terms of
  safety and efficacy
• A comprehensive review of the pipeline for AML
  therapies, including individual analysis of a
  number of late-stage pipeline drugs that have the
  potential to enter the market during the forecast
  period. The pipeline is analyzed on the basis of
  Phase distribution, molecule types and molecular
  targets, as well as administration routes
• An additional in-depth analysis of pipeline drug
  clinical trials by phase, trial size, trial
  duration and program failure rate analyses for
  each molecule type and molecular target

6
Reasons to buy

• The report will assist business development and
  enable marketing executives to strategize their
  product launches, by allowing them to
• Understand the efficacy and safety of the current
  monotherapies and drug combinations used in the
  treatment of AML, with in-depth analysis of the
  disease treatment algorithm
• Understand the key signaling pathways and
  molecular targets currently under investigation
  in drug development for AML
• Understand the vast scope of the pipeline,
  including which molecule types and molecular
  targets are most prominent
• Observe the trends in clinical trial duration and
  size by clinical phase and molecule type, and use
  the clinical trial failure rate analysis to
  assess the risk profiles of current and/or future
  developmental programs for AML cancer
  therapeutics
• Assess the potential clinical and commercial
  impact of current late-stage pipeline molecules
  in the AML therapeutics market

7
Table Of Content


1 Table of Contents 41.1 List of Tables 81.2
List of Figures 92 Introduction 112.1 Disease
Introduction 122.2 Epidemiology 122.3 Symptoms
122.4 Risk Factors 132.4.1 Age 132.4.2 Gender
132.4.3 Smoking 132.4.4 Chemotherapy or
Radiation Therapy 132.4.5 Benzene 132.4.6
Previous Myelodysplastic Syndrome 132.4.7
Chromosomal Disorders or Genetic Mutations 132.5
Diagnostic Techniques 142.5.1 Blood Tests and
Immunophenotyping 14
8
Table Of Content


2.5.2 Flow-Cytometry 142.5.3 Cytogenetic
Analysis 142.5.4 Molecular Diagnostics 142.6
Pathophysiology 142.7 Diagnostic Criteria 162.8
Prognosis and Survival 183 Treatment Algorithm
213.1 Treatment of Acute Promyelocytic (M3)
Leukemia is Effective, with High Cure Rates
223.2 Clinical Trial Response Criteria 223.3
Remission Induction Therapy 233.3.1 Intensive
Remission Induction Therapy 233.3.2
Non-intensive Remission Induction Therapy 313.4
Consolidation Therapy 373.4.1 High- or Low-dose
Cytarabine-based Therapy 373.4.2 Stem Cell
Transplantation 39 3.5 Remission Re-induction in
Relapsed Disease 41
9
Table Of Content


3.5.1 Salvage Chemotherapy 423.5.2 HSCT in
Relapsed Disease 434 Commercial and Clinical
Prospects of Marketed Products 474.1 Cytarabine
474.2 Daunorubicin 484.3 Idarubicin 484.4
Vidaza 494.5 Dacogen 504.6 Mitoxantrone 514.7
Etoposide 524.8 Fludarabine 53 4.9 Busulfan
544.10 Cyclophosphamide 54Get full TOC at
http//www.reportsandintelligence.com/acute-myeloi
d-leukemia-therapeutics-to-2020-novel-therapies-to
-offer-clinical-benefit-in-small-patient-cohorts-m
arket/table-of-contents
10

FOR MORE DETAILS
Visit us at
http//www.reportsandintelligence.com/acute-myeloi
d-leukemia-therapeutics-to-2020-novel-therapies-to
-offer-clinical-benefit-in-small-patient-cohorts-m
arket
Stay With Us
TELEPHONE Direct 1 [phone] Toll Free
1 [phone]E-MAIL sales_at_reportsandintellig
ence.com
5933 NE Win Sivers Drive,205, Portland, OR
97220United States